伊伐布雷定的临床应用
本文综述伊伐布雷定通过选择性抑制窦房结If电流降低心率的作用机制,及其在收缩性心力衰竭和慢性稳定型心绞痛患者中的评估与应用,并提及对不适当窦性心动过速的潜在作用。
要点
- 伊伐布雷定选择性抑制窦房结If电流,降低舒张期去极化速率从而减慢心率。
- 该药已用于特定收缩性心力衰竭和慢性稳定型心绞痛患者,无临床显著不良反应。
- 尚未批准用于其他适应证,但对不适当窦性心动过速显示出应用前景。
核心结论
- 伊伐布雷定基于其独特的作用机制,临床用途不断演变,已用于特定收缩性心力衰竭和慢性稳定型心绞痛患者。
研究设计与样本
- 本文为综述,回顾伊伐布雷定的作用机制及推动其当前临床适应证和用法的重要研究。
主要发现
- 伊伐布雷定选择性抑制窦房结组织中的If电流,降低舒张期去极化速率,从而减慢心率。
- 该机制区别于其他负性变时药物,已在特定收缩性心力衰竭和慢性稳定型心绞痛患者中评估并使用,无临床显著不良反应。
- 虽未批准用于其他适应证,伊伐布雷定在不适当窦性心动过速的管理中显示出前景。
临床怎么用
- 基于综述所述,伊伐布雷定可用于特定收缩性心力衰竭和慢性稳定型心绞痛患者以减慢心率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical use of ivabradine has and continues to evolve along channels that are predicated on its mechanism of action. It selectively inhibits the funny current (If) in sinoatrial nodal tissue, resulting in a decrease in the rate of diastolic depolarization and, consequently, the heart rate, a mechanism that is distinct from those of other negative chronotropic agents. Thus, it has been evaluated and is used in select patients with systolic heart failure and chronic stable angina without clinically significant adverse effects. Although not approved for other indications, ivabradine has also shown promise in the management of inappropriate sinus tachycardia. Here, the authors review the mechanism of action of ivabradine and salient studies that have led to its current clinical indications and use.
引用
- Koruth JS, Lala A, Pinney S, et al. The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017. PMID: 28958335. doi:10.1016/j.jacc.2017.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。